ADMA Biologics, Inc. Revenue 2011–2025
ADMA Biologics, Inc. reported $510.17M of revenue for fiscal 2025. That was 19.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +1108.4%.
| Fiscal year | Revenue | Change (YoY) |
|---|---|---|
| FY 2025 | $510.17M | +19.6% |
| FY 2024 | $426.45M | +65.2% |
| FY 2023 | $258.21M | +67.6% |
| FY 2022 | $154.08M | +90.4% |
| FY 2021 | $80.94M | +91.7% |
| FY 2020 | $42.22M | +43.9% |
| FY 2019 | $29.35M | +72.8% |
| FY 2018 | $16.99M | -25.4% |
| FY 2017 | $22.76M | +113.5% |
| FY 2016 | $10.66M | +48.5% |
| FY 2015 | $7.18M | +21.3% |
| FY 2014 | $5.92M | +92.8% |
| FY 2013 | $3.07M | +174.4% |
| FY 2012 | $1.12M | +46.9% |
| FY 2011 | $761,042 | — |
Source: ADMA Biologics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ADMA 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
ADMA Biologics, Inc. reported $510.17M of revenue for fiscal 2025. That was 19.6% higher than fiscal 2024. Compared with fiscal 2020, the change was +1108.4%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for ADMA Biologics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeADMA Biologics, Inc. — frequently asked questions
What is ADMA Biologics, Inc.'s revenue?
ADMA Biologics, Inc. (ADMA) reported revenue of $510.17M for fiscal year 2025, per its SEC filings.
How has ADMA Biologics, Inc.'s revenue changed over time?
Between fiscal 2011 and 2025, ADMA's revenue grew at roughly 59.2% per year (compound annual rate), from $761,042 to $510.17M.
Where does this data come from?
Figures are computed from ADMA Biologics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.